| Literature DB >> 28258730 |
Celestino Sardu1, Gaetano Santulli2, Matteo Santamaria3, Michelangela Barbieri4, Cosimo Sacra3, Pasquale Paolisso4, Fabio D'Amico3, Nicola Testa3, Igor Caporaso3, Giuseppe Paolisso3, Raffaele Marfella4, Maria Rosaria Rizzo4.
Abstract
Catheter ablation (CA) is a procedure commonly used to restore sinus rhythm in patients with atrial fibrillation (AF). However, AF recurrence after CA remains a relevant clinical issue. We tested the effects of an oral antioxidant treatment (alpha lipoic acid [ALA]) on AF recurrence post-CA. Patients with paroxysmal AF have been enrolled in a randomized, prospective, double-blind, controlled placebo trial. After CA, patients have been randomly assigned to receive ALA oral supplementation (ALA group) or placebo (control group) and evaluated at baseline and after a 12-month follow-up: 73 patients completed the 12-month follow-up (ALA: 33 and control: 40). No significant difference has been detected between the 2 groups at baseline. Strikingly, 1 year after CA, ALA therapy significantly reduced serum markers of inflammation. However, there was no significant difference in AF recurrence events at follow-up comparing ALA with placebo group. Multivariate analysis revealed that the only independent prognostic risk factor for AF recurrence after CA is age. In conclusion, ALA therapy reduces serum levels of common markers of inflammation in ablated patients. Nevertheless, ALA does not prevent AF recurrence after an ablative treatment.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28258730 PMCID： PMC5392151 DOI： 10.1016/j.amjcard.2017.01.040
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778